Open-label Extension Study in Participants With Early Alzheimer's Disease (NCT07105709)
A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease
🩺 Plain-English Summary (8th-Grade Level)
The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same study medicine. Participants must already be in study 219867 to be able to take part in this study. This study will assess the long-term safety and efficacy of GSK4527226 in participants with early AD (including mild cognitive impairment \[MCI\] and mild dementia due to AD) who have completed the parent study.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Maitland, Florida
Age range: 50 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- GSK Investigational Site — Maitland, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Stuart, Florida
- GSK Investigational Site — Toms River, New Jersey
- GSK Investigational Site — Staten Island, New York
- GSK Investigational Site — Matthews, North Carolina
- GSK Investigational Site — Oklahoma City, Oklahoma
- GSK Investigational Site — Houston, Texas
- GSK Investigational Site — Fairfax, Virginia
- GSK Investigational Site — Buenos Aires,
- GSK Investigational Site — Buenos Aires,
- GSK Investigational Site — Ciudad Autonoma de Buenos Aire,
- GSK Investigational Site — Ciudad Autonoma de Bueno,
- GSK Investigational Site — Macquarie Park, New South Wales
- GSK Investigational Site — Nedlands, Western Australia
- GSK Investigational Site — Ottawa, Ontario
- GSK Investigational Site — Peterborough, Ontario
- GSK Investigational Site — Toronto, Ontario
- GSK Investigational Site — Greenfield Park, Quebec
- GSK Investigational Site — Sherbrooke, Quebec
- GSK Investigational Site — Oulu,
- GSK Investigational Site — Bergen,
- GSK Investigational Site — Oslo,
- GSK Investigational Site — Junggu,
- GSK Investigational Site — Barcelona,
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer's Disease
- Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia — Calgary, Alberta
- A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology — Clermont, Florida
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease — Phoenix, Arizona
- DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease — Birmingham, Alabama
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Birmingham, Alabama
- A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Chandler, Arizona
Explore by condition: All Alzheimer's Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.